NEW YORK (GenomeWeb News) – Genetic Technologies said late last week that it has settled with Reproductive Genetics Institute over allegations that RGI infringed GTG's patent covering its non-coding DNA technology.
Terms of the settlement were not disclosed.
GTG sued RGI last August alleging Chicago-based RGI infringed US Patent No. 5,612,179 titled "Intron Sequence Analysis Method for Adjacent Locus Alleles as Haplotypes," with its screening services for cystic fibrosis. GTG, based in Melbourne, Australia, had asked the US District Court for the Northern District of Illinois Eastern Division for unspecified damages.
Last week, GTG announced a deal to settle patent infringement allegations it leveled against Bioscientia Institute.